Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis

SIMPLE SUMMARY: Chimeric antigen receptor-modified T cells (CAR-T) have shown great success in the treatment of B-cell leukemia. However, their efficacy is compromised in B-cell-derived lymphoma and solid tumors. Optimization of CAR design to improve in vivo persistence is a focus of current CAR-T c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haiyong, Han, Ping, Qi, Xinyue, Li, Fanlin, Li, Min, Fan, Lilv, Zhang, Huihui, Zhang, Xiaoqing, Yang, Xuanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827522/
https://www.ncbi.nlm.nih.gov/pubmed/33429845
http://dx.doi.org/10.3390/cancers13020197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827522/
https://www.ncbi.nlm.nih.gov/pubmed/33429845
http://dx.doi.org/10.3390/cancers13020197

Ejemplares similares